Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

Authors

Robert A. Larsen, University of Southern California
Peter G. Pappas, University of Alabama - Birmingham
John Perfect, Duke University
Judith A. Aberg, Washington University School of Medicine in St. LouisFollow
Arturo Casadevall, Albert Einstein College of Medicine
Gretchen A. Cloud, University of Alabama - Birmingham
Robert James, Rho Federal Systems Division, Inc.
Scott Filler, Harbor-UCLA Research and Education Institute
William E. Dismukes, University of Alabama - Birmingham

Journal

Antimicrobial Agents and Chemotherapy

Publication Date

2005

Volume

49

Issue

3

Inclusive Pages

952

Document Type

Open Access Publication

DOI

10.1128/AAC.49.3.952-958.2005

Rights and Permissions

Larsen, R. A., Pappas, P. G., Perfect, J., Aberg, J. A., Casadevall, A., Cloud, G. A., . . . Dismukes, W. E. (2005). Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrobial Agents and Chemotherapy, 49(3), 952-958. DOI:10.1128/AAC.49.3.952-958.2005

Recommended Citation

Larsen, Robert A.; Pappas, Peter G.; Perfect, John; Aberg, Judith A.; Casadevall, Arturo; Cloud, Gretchen A.; James, Robert; Filler, Scott; and Dismukes, William E., "Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis." Antimicrobial Agents and Chemotherapy. 49, 3. 952. (2005).
https://digitalcommons.wustl.edu/open_access_pubs/2357